◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › LBRX

LB Pharmaceuticals Inc (LBRX) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-20

LB Pharmaceuticals Inc (LBRX) operates in the Biotechnology industry and is headquartered in New York, United States with about 35 employees. Its market capitalization is roughly $901 million. In the fiscal year ended 2025-12-31, LBRX reported $0M in revenue and ($25M) in net income.

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.

Interactive charts & full statements →

LBRX Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($30M)($65M)($11M)($3M)
Net Income($25M)($63M)($6M)($14M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LBRX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($22M)($14M)($5M)($5M)($6M)
Net Income($19M)($12M)($4M)($5M)($5M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LBRX Free Cash Flow History

LBRX Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-31
Total Assets$313M$34M$46M$22M
Total Liabilities$12M$128M$80M$50M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LBRX viewer.

Other Companies in Biotechnology

← LBRTAll stocksLBTYA →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.